Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

NCT ID: NCT05282459

Last Updated: 2025-03-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-12
• Study Completion Date: 2025-03-03

Brief Summary

This is a phase 1b/2, open-label, single arm study to evaluate if enasidenib is safe and effective in improving anemia and decreasing transfusion needs in subjects diagnosed with lower risk myelodysplastic syndrome (MDS) or nonproliferative chronic myelomonocytic leukemia (CMML) without a mutation in isocitrate dehydrogenase type 2 (IDH2 wildtype). Other objectives include assessment of improvements in platelet production and characterization of the mechanism of action of enasidenib in enhancing endogenous erythropoiesis.

Detailed Description

Primary Objective(s)- To determine the efficacy (response rate) of enasidenib in improving anemia and decreasing RBC transfusion dependence.

Secondary Objective(s)- To determine the tolerability, safety and durability of the erythroid response and identify laboratory parameters as clinical markers of response.

Conditions

Leukemia; Leukemia, Myeloid; Monocytic Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Enasidenib mesylat

Participants will self administer the enasidenib orally everyday.

Group Type: EXPERIMENTAL

Enasidenib mesylat dose escalation

Intervention Type: DRUG

Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.

Interventions

Enasidenib mesylat dose escalation

Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.

Intervention Type: DRUG

Other Intervention Names

(Idhifa, AG 221)

Eligibility Criteria

Inclusion Criteria

1. Documented diagnosis of

• MDS according to WHO/FAB classification that meets IRSS-R classification of low or intermediate risk disease; and a diagnosed as denovo or secondary MDS (MDS-RS eligible if refractory to or declined luspatercept therapy) OR
• Dysplastic (nonproliferative) CMML with WBC < 13.0/microL)

2. No disease-modifying therapy (HMA, hydrea) within 2 months of starting study

3. Age ≥ 18 years of age

4. ECOG ≤ 3

5. Negative for IDH2 mutation by NGS or multiplex PCR (SNaPshot)

6. Has symptomatic anemia defined as hemoglobin < 10.5 g/dL with any of the following.

• Tachypnea
• Shortness of breath
• Fatigue
• Malaise
• Worsening of cardiovascular function
• Asthenia
• Dyspnea on exertion
• Angina
• Other subject symptoms the subject reports as being associated with being anemic.

7. Stated willingness to comply with all study procedures and availability for the duration of the study

8. Ability to take oral medication and be willing to adhere to the medication regimen.

9. Females of reproductive potential need to either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with highly effective contraception without interruption, 28 days prior to starting enasidenib, during the study therapy, and for 30 days after last dose of enasidenib

10. For males of reproductive potential: agreement to use of condoms

11. Adequate organ function defined as:

• Hepatic function: total bilirubin <1.5 x ULN (unless attributable to Gilbert's disease), AST or ALT < 3x ULN
• Renal function: creatinine clearance > 30 mL/minute, calculated by Cockcroft-Gault formula

12. Ability to understand and the willingness to sign the IRB approved informed consent document.

13. Women of childbearing potential must have negative urine or serum pregnancy test

Exclusion Criteria

1. Use of concurrent other erythropoietic agents (including epoetin, darbepoetin), G-CSF within 30 days of study enrollment

2. Less than 3 months of life expectancy

3. Significant cardiac disease (NYHA Class IV congestive heart failure, or unstable angina or myocardial infarction within the last 6 months

4. Harbor IDH2 somatic mutations by NGS or PCR

5. Pregnant or breast feeding

6. Any uncontrolled bacterial, fungal, viral or other infection.

7. No known HIV+ or active hepatitis B or C infection, defined as positive viral load for HBV or HCV or a positive surface antigen (HBsAg) test for hepatitis B.

8. Have other causes of anemia: deficiencies in iron, B12, folate; nutritional deficiencies related to gastric surgery, anorexia nervosa, excessive zinc supplementation; gastrointestinal bleed. If nutritional deficiencies can be corrected, potential subject can be rescreened and enrolled if nutritionally replete and still meets eligibility criteria.

9. Any other medical history, including laboratory results, deemed by the Principal Investigator likely to interfere with their participation in the study, or to interfere with the interpretation of the results

10. Pregnant or breast feeding

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene Corporation

INDUSTRY

Sponsor Role: collaborator

Stanford University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tian Yi Zhang, MD

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Stanford Cancer Institute

Palo Alto, California, United States

Countries

United States

Other Identifiers

HEM0056

Identifier Type: OTHER

Identifier Source: secondary_id

NCI-2022-02837

Identifier Type: OTHER

Identifier Source: secondary_id

IRB- 62692

Identifier Type: -

Identifier Source: org_study_id